PROVENTION BIO, INC.

PRVB NASDAQ
12.27
+1.31
+11.95%
Closed 18:44 06/21 EDT
Open
11.14
Prev Close
10.96
High
12.62
Low
10.76
Volume
1.13M
Avg Vol (3M)
761.70K
52 Week High
22.82
52 Week Low
1.520
% Turnover
3.04%
Market Cap
458.43M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers PROVENTION BIO, INC. PRVB stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
MORE >

Recently

Name
Price
%Change